Dear Editor,
The SARS-CoV-2 infection can lead to severe acute respiratory distress syndrome (ARDS) with prolonged mechanical ventilation (MV). Patients with coronavirus disease 2019 (COVID-19) associated ARDS usually met the diagnosis criteria for sepsis-associated immunosuppression as acquired infections, primarily bacterial and fungal co-infections [1], are frequently encountered. Such secondary infections are associated with late mortality. Herpesviridae reactivation is common in non-immunocompromised patients with prolonged MV and could be responsible for increased mortality and longer duration of MV in ICU [2, 3]. Although the diagnosis of Herpesviridae pulmonary infection is challenging and not consensual in critically ill patients, therapeutic strategies are available to reduce morbidity and mortality [4]. As viral co-infections in these patients remain poorly investigated, we aimed to describe Herpesviridae pulmonary reactivations in patients with COVID-19 ARDS.
Anzeige
Methods
We reviewed all virology results for patients admitted to Rennes University Hospital (Rennes, France) for COVID-19 ARDS between March 3, 2020, and April 15, 2020. SARS-CoV-2 infection was confirmed by polymerase chain reaction (PCR). Patients mechanically ventilated longer than 7 days and who had negative PCR for herpes simplex virus (HSV) and cytomegalovirus (CMV) were included in the analysis. Herpes simplex virus and cytomegalovirus replication were measured by quantitative real-time PCR on tracheal aspirates twice a week for each patient. Herpesviridae reactivation was defined as two consecutive positive HSV or CMV PCR on tracheal aspirates. The Mann-Whitney rank sum test was used to compare non-parametric continuous variables, and qualitative data were compared using Fisher’s exact test. Statistical significance was defined as P < .05. PRISM version 8 (GraphPad Software, San Diego, CA, USA) was used to perform statistical analyses.
Results
A total of 38 patients were included. Table 1 shows the demographic, clinical, and biological characteristics of the included patients. The mean age was 59 years (interquartile range (IQR), 54–71), and 27 (71%) were male. Of these 38 patients, 18 (47%) presented at least one viral pulmonary reactivation. Nine patients had HSV reactivation alone, 2 presented CMV reactivation alone, and 7 had co-reactivation. Herpesviridae infection was diagnosed at a median of 9 days (IQR, 5–14). The median number of positive samples was 3 (IQR, 2–5).
Table 1
ARDS COVID patient’s characteristics at ICU admission
All patients (n = 38) | No Herpesviridae reactivation (n = 20) | Herpesviridae reactivation (n = 18) | P value | |
|---|---|---|---|---|
Demographic characteristics | ||||
Age, years | 59 (54–71) | 57 (48–69) | 64 (55–72) | 0.07 |
Sex | ||||
Men | 27 (71) | 15 (75) | 12 (67) | > 0.99 |
Women | 11 (29) | 5 (25) | 6 (33) | |
BMI | 24 (24–31) | 27 (23–27) | 26.9 (24–29) | 0.78 |
Current smoking | 2 (5) | 1 (5) | 1 (5) | 0.94 |
Coexisting conditions | ||||
Any | 19 (50) | 10 (50) | 9 (50) | > 0.99 |
Diabetes | 15 (40.5) | 7 (35) | 8 (44) | 0.55 |
Cancer | 3 (8) | 2 (10) | 1 (5) | > 0.99 |
Clinical and biological baseline characteristics | ||||
White blood cell count (109/L) | 10.1 (3.4–13) | 7.8 (6–10.4) | 11.2 (7.3–13.2) | 0.07 |
Lymphocyte count (109/L) | 0.74 (0.59–1.04) | 0.79 (0.53–1.06) | 0.83 (0.7–1.23) | 0.29 |
Ratio of PaO2 to FiO2 | 106 (95–170) | 90 (69–142) | 116 (90–147) | 0.15 |
SAPS II score on day 1 | 42 (31–58) | 39 (29–61) | 42 (33–55) | 0.65 |
SOFA score on day 1 | 3 (2–7) | 7 (2–9) | 3 (2–7) | 0.81 |
Patients with Herpesviridae reactivation had significantly longer duration of MV compared with patients without Herpesviridae reactivation. Table 2 shows outcomes of patients according to Herpesviridae reactivation status.
Table 2
Treatments and clinical course of COVID-19 patients according to Herpesviridae status
All patients (n = 38) | No Herpesviridae reactivation (n = 20) | Herpesviridae reactivation (n = 18) | P value | |
|---|---|---|---|---|
Antibiotics | 38 (100) | 20 (100) | 18 (100) | 0.99 |
Antiviral | 32 (84) | 16 (80) | 16 (89) | 0.66 |
Steroids | 12 (32) | 4 (20) | 8 (44) | 0.16 |
ECMO | 3 (8) | 1 (5) | 2 (11) | 0.49 |
Duration of NMB infusion | 6 (3–11) | 5 (3–8) | 6 (3–11) | 0.73 |
Renal replacement therapy | 9 (24) | 5 (25) | 4 (22) | 0.99 |
Prone positioning ventilation | 21 (55) | 11 (52) | 10 (56) | 0.24 |
Duration of mechanical ventilation | 18 (13–25) | 9 (6–14) | 23 (18–39) | 0.0001 |
Ventilator-free days at day 28 | 8 (0–15) | 14 (7–20) | 2 (0–3) | 0.0008 |
Ratio of PaO2 to FiO2 on day 7 | 193 (135–248) | 212 (160–260) | 178 (135–195) | 0.04 |
Ratio of PaO2 to FiO2 on day 14 | 216 (174–308) | 280 (222–401) | 186 (114–233) | 0.01 |
SOFA score on day 7 | 7 (5–11) | 7 (5–10) | 10 (6–11) | 0.19 |
SOFA score on day 14 | 7 (2–10) | 3 (1–10) | 7 (2–10) | 0.39 |
Bacterial VAP | 9 (24) | 3 (15) | 6 (33) | 0.18 |
ICU length of stay | 23 (16–34) | 16 (12–24) | 29 (24–47) | 0.0001 |
Death in ICU | 4 (10.5) | 2 (10) | 2 (11) | 0.99 |
Discussion
Our findings suggest that Herpesviridae reactivations are frequent in patients with COVID-19 ARDS, with higher rates than those described in previous studies performed in critically ill patients [2, 3]. This result was expected since severe forms of COVID-19 ARDS are associated with biological and clinical markers of acquired immunosuppression such as lymphopenia [1]. This state of immunodeficiency probably plays a role in the occurrence of viral reactivations.
Anzeige
Among the most frequent risk factors for CMV and HSV reactivation in the ICU patients, sepsis and prolonged MV have been described in several studies [5, 6]. COVID-19 patients develop typical clinical and biological manifestations of septic shock [1]. There is no clear evidence that Herpesviridae reactivations induce difficulties to wean patients from MV nor increase the length of stay in COVID-19 patients, and our sample size did not allow us to perform a multivariate analysis. Larger studies are needed to explore such association. However, previous observational studies [5, 6] showed that Herpesviridae detection in the lower respiratory tract is associated with poorer outcomes.
Finally, our results suggest that SARS-CoV-2 infection could be a risk factor for Herpesviridae reactivation. Rapid identification of these co-infections seems warranted as it may impact the prognosis of infected patients. However, the direct consequences and the usefulness of antiviral treatments for these Herpesviridae infections remain factors that deserve to be investigated.
Acknowledgements
None
Ethics approval and consent to participate
The study was approved by Rennes University Hospital’s review board (no. 16-117).
Consent for publication
Not applicable
Competing interests
The authors report no conflict of interest related to this work.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.